ANKLE2 and ovarian carcinoma: Using RNAi to silence ANKLE2 in various human ovarian cancer cell lines (SKOV3, OVCAR, and APOCC) decreases cell viability and cell migration, and increases chemosensitivity to paclitaxel, a common chemotherapy used in ovarian cancer (Al-Farsi et al., 2022).